Veligrotug, the newly FDA‑approved drug for thyroid eye disease (TED), showed measurable benefits in a recent clinical trial, offering an additional option alongside the existing therapy teprotumumab.
Trial results show reduction in eye bulging and double vision
In the THRIVE study (NCT05176639), patients receiving veligrotug experienced an average decrease of 2.9 mm in proptosis, the forward protrusion of the eye that characterizes the condition. The same trial reported that 59 % of participants on the medication reported improvement in diplopia, or double vision, versus 20 % among those given a placebo.
Dr. Michael Yen, an oculoplastic surgeon at Baylor College of Medicine and a lead author of the study, noted that a 2.9 mm shift may appear modest but translates into a noticeable change in appearance and comfort for affected individuals. He added that 70 % of study participants achieved at least a 2‑mm reduction in eye protrusion.
Safety profile and side effects
Adverse events were documented, including transient hearing disturbances and menstrual cycle interruptions in younger women. The menstrual irregularities resolved after treatment cessation, and the remaining side effects subsided over time. Researchers emphasized that clinicians should weigh these risks against the potential visual and quality‑of‑life gains.
While the drug adds to the limited arsenal for TED, the overall safety data remain consistent with expectations for a targeted therapy in this patient population.
TED often follows an overactive thyroid condition, causing tissue inflammation behind the eyes. Patients may experience bulging, double vision, and eye‑pain that impair daily activities. Prior to veligrotug’s approval, teprotumumab was the sole biologic approved for this indication, and many clinicians relied on steroids or radiation therapy despite their side‑effect profiles.
Related: Users Report Unexpected Account Blocks Across Platforms
Veligrotug works by inhibiting a specific receptor involved in the inflammatory cascade that drives tissue expansion. By blocking this pathway, the medication reduces swelling and restores ocular alignment. The mechanism differs from teprotumumab, which targets a related growth factor receptor, offering physicians a distinct therapeutic angle.
In practice, the new option may allow doctors to tailor treatment sequences. For example, a patient who experiences intolerable side effects from teprotumumab could switch to veligrotug without restarting the entire therapeutic cycle. This flexibility could shorten recovery times and improve overall satisfaction.
Clinicians are already incorporating the findings into treatment guidelines. The latest consensus recommends evaluating disease severity, patient comorbidities, and prior response before selecting a biologic. Such individualized approaches aim to maximize benefit while minimizing adverse outcomes.
Looking ahead, the emergence of veligrotug may influence treatment pathways, especially as physicians seek alternatives that balance efficacy with tolerability. If additional agents continue to demonstrate comparable outcomes, clinicians could tailor therapy to individual patient needs, potentially reducing reliance on a single drug.
For patients, the availability of another FDA‑approved option could expand access to care and provide a fallback if existing treatments prove unsuitable. Ongoing monitoring will determine whether the initial promise translates into broader, real‑world benefits.
